Tamtam Try Tamtam free
Merck logo

Merck account plan

Leading-edge science saves lives

At a glance

Merck & Co. (MSD outside the US and Canada) sells prescription medicines, vaccines and animal health products, with $65,011 million of 2025 sales.

Merck & Co., Inc., based in Rahway, New Jersey and known as MSD outside the US and Canada, delivers prescription medicines, biologic therapies, vaccines and animal health products. Human medicines go to wholesalers, retailers, hospitals, governments and managed care; animal health products to veterinarians, distributors, producers, farmers and pet owners. Total 2025 sales were $65,011 million (+1%), with GAAP net income of $18,254 million; the US accounted for $36,510 million. Keytruda alone was 49% of 2025 sales. Merck had about 75,000 employees at the end of 2025, about 24,700 of them in research, and is led by Chairman and CEO Robert M. Davis.

Business units

Strategic priorities

New growth drivers beyond Keytruda
Merck sees greater than $70 billion of commercial opportunity from over 20 new products by the mid-2030s, with 10 programs representing the majority to be de-risked by end-2027.
Diversified oncology
Oncology is built on three pillars: immuno-oncology, precision molecular targeting and antibody-drug conjugates such as sacituzumab tirumotecan, which has 17 Phase 3 studies.
New launches
Winrevair, Capvaxive, Welireg, Ohtuvayre, Enflonsia and Lipfendra, the first once-daily oral PCSK9 inhibitor approved in 2026, are the near-term growth products.
Business development
Business development remains a high priority, with up to $15 billion described as the sweet spot and larger deals possible for the right science.
Cost optimisation reinvested
The 2025 Restructuring Program targets about $1.7 billion of annual savings by end-2027, within a multiyear initiative aiming at $3.0 billion of annual savings, fully reinvested into growth areas.

Latest results

In Q2 2026 Merck's sales rose 5% to $16,607 million, with Keytruda/Keytruda Qlex at $8,366 million (+5%), Winrevair at $588 million (+75%) and Welireg at $271 million (+67%), while Januvia/Janumet fell 31%. It posted a GAAP loss per share of $0.54 because of a $5.7 billion charge for the $6.8 billion Terns Pharmaceuticals acquisition. Full-year 2026 sales guidance was raised to $66.3-67.3 billion, growth of 2% to 4%, with non-GAAP EPS of $2.66-2.76 after one-time charges for Cidara and Terns.

Investments and deals

Verona Pharma acquisition
Acquired for $10.4 billion in October 2025, adding Ohtuvayre for COPD.
Cidara Therapeutics acquisition
Acquired for about $9.2 billion in January 2026, bringing MK-1406, a long-acting flu antiviral seen at greater than $5 billion in revenue potential.
Terns Pharmaceuticals acquisition
Completed for $6.8 billion in 2026, adding MK-4208 for chronic myeloid leukemia.
Capital projects
About $20 billion of capital projects planned over 2025-2029, more than $12 billion in the US.
Restructuring
The 2025 Restructuring Program costs about $3.0 billion and covers job eliminations, a smaller real estate footprint and manufacturing optimisation.

Challenges and risks

Keytruda concentration and loss of exclusivity
Keytruda was 49% of 2025 sales; its compound patent expires December 2028, and it is expected to be selected for IRA price setting in 2027, effective 2029.
Generic erosion in 2026
Januvia/Janumet and Bridion lose US exclusivity in 2026, part of a headwind of about $2.5 billion from generics, IRA price setting and Koselugo.
US pricing pressure
IRA price setting, Medicaid and 340B rules and the December 2025 most-favored-nation agreement with the US government weigh on pricing.
China vaccine demand
Gardasil shipments to China were paused and China sales fell from $5,494 million to $1,939 million in 2025.

What leadership says

“I believe Merck is substantially stronger, more diversified, and better positioned for sustainable growth than it was just 5 years ago.”

Robert M. Davis, Chairman and Chief Executive Officer · Q2 2026 earnings call, 4 August 2026

“we see that as the LOE period as more of a hill than a cliff”

Robert M. Davis, Chairman and Chief Executive Officer · On the Keytruda loss of exclusivity, Q2 2026 earnings call, 4 August 2026

“The transformation of our portfolio is well underway, and momentum is building”

Robert M. Davis, Chairman and Chief Executive Officer · Q4 2025 earnings call, 3 February 2026

Where a supplier can help

Launch support
With Lipfendra, Winrevair, Capvaxive and other new products driving the post-Keytruda plan, there is demand for commercial, market access and patient-support services.
Manufacturing capacity build
The about $20 billion capital projects plan, mostly in the US, opens doors for engineering, construction and manufacturing equipment suppliers.
Efficiency programmes
The restructuring targets of $1.7 billion and $3.0 billion of annual savings favour suppliers that cut real estate, sales and administrative costs.
Acquisition integration
Successive deals (Verona Pharma, Cidara, Terns) and the business development appetite call for integration and due-diligence support.
Clinical trial operations
About 80 Phase 3 studies underway point to demand for CRO, trial technology and data services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Merck?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Merck

What does Merck & Co. do?

Merck & Co. (MSD outside the US and Canada) develops and sells prescription medicines, vaccines and animal health products, with Keytruda as its largest product.

What was Merck & Co.'s revenue in 2025?

Total 2025 sales were $65,011 million, up 1%, with GAAP net income of $18,254 million.

How many employees does Merck & Co. have?

About 75,000 at the end of 2025, about 30,000 of them in the US.

Who leads Merck & Co.?

Robert M. Davis is Chairman, CEO and President; Caroline Litchfield is CFO and Dean Li heads Merck Research Laboratories.

How is Merck preparing for Keytruda's loss of exclusivity?

It is building over 20 new growth drivers worth greater than $70 billion of commercial opportunity by the mid-2030s, through launches, its pipeline and acquisitions such as Verona Pharma, Cidara and Terns.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)